By Fineline Cube 
US-based pharmaceutical giant Pfizer Inc. (NYSE: PFE) announced a significant leadership and organizational restructuring in China, effective March 18, 2025. The move aims to enhance the company’s growth and innovation capabilities in the Chinese market.
Organizational Changes
The restructuring involves merging the retail business team and national bidding team with the original business team to form a new business and retail department. This integration is designed to improve operational efficiency, accelerate new product launches, extend the lifecycle of mature products, and maximize synergies between sales channels.
Leadership Appointments
Mr. Cao Zhi has been appointed as the head of the newly established business and retail department, reporting directly to the President of Pfizer China. Meanwhile, Ms. Wang Yu, the general manager of Pfizer China’s Oncology Business Unit, has decided to leave the company for new career opportunities. Ms. Li Jinhui will take over as the general manager of the oncology and rare diseases division. Additionally, Mr. Xu Decai, head of the basic business of the hospital emergency and blood and rare diseases division, will serve as the acting general manager of the hospital emergency division, reporting directly to the President of Pfizer China.-Fineline Info & Tech